Evidence map›Paper›PMID 25999351›Full record

ArticleOncotarget2015

Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.

Tiyasha H Ayub, Mignon-Denise Keyver-Paik, Manuel Debald, Babak Rostamzadeh, Thore Thiesler, Lars Schröder, Winfried Barchet, Alina Abramian, Christina Kaiser, Glen Kristiansen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Effect ofInternational journal of molecular sciences · 2022
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tiyasha H AyubDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany.
Mignon-Denise Keyver-PaikDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany.
Manuel DebaldDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany.
Babak RostamzadehInstitute of Pathology, Center for Integrated Oncology, Sigmund-Freud-Strasse, Bonn, Germany.
Thore ThieslerInstitute of Pathology, Center for Integrated Oncology, Sigmund-Freud-Strasse, Bonn, Germany.
Lars SchröderDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany.
Winfried BarchetInstitute of Clinical Chemistry and Clinical Pharmacology, Center for Integrated Oncology, Sigmund-Freud-Strasse, Bonn, Germany.
Alina AbramianDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany.
Christina KaiserDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany.
Glen KristiansenInstitute of Pathology, Center for Integrated Oncology, Sigmund-Freud-Strasse, Bonn, Germany.
Walther KuhnDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany.
Kirsten KüblerDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matched samples before and after taxane/platinum-based neoadjuvant chemotherapy. All used markers of stemness (ALDH1, CD24, CD117, CD133) isolated low frequencies of malignant cells. ALDH1 was the most valuable marker for tracking stemness in vivo. The enrichment of ALDH1 expression after treatment was associated with a poor response to chemotherapy, with platinum resistance and independently prognosticated unfavorable outcome. Our results suggest that increased ALDH1 expression after treatment identifies patients with aggressive tumor phenotypes.

Indexed as

Drug Resistance, NeoplasmNeoadjuvant TherapyAC133 AntigenAdultAgedAldehyde Dehydrogenase 1 FamilyAntigens, CDBiomarkers, TumorBridged-Ring CompoundsCD24 AntigenFemaleGlycoproteinsHumansIsoenzymesMiddle AgedNeoplasm Recurrence, LocalAC133 AntigenAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanAntigens, CDBiomarkers, TumorBridged-Ring CompoundsCD24 AntigenCD24 protein, humanGlycoproteinsIsoenzymesPeptidesPlatinum CompoundsPROM1 protein, humanProto-Oncogene Proteins c-kitRetinal DehydrogenasetaxaneTaxoidsALDH1cancer stem-like cellovarian cancerpredictive markerprognostic marker

Identifiers

PMID25999351
PMCPMC4599280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.